Monica Motwani

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 501 citations · Full text

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

Hope S. Rugo, Aditya Bardia, Frederik Marmé et al. · The Lancet · 2023 · 363 citations · Full text

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos et al. · Cancer Chemotherapy and Pharmacology · 2014 · 155 citations

Oncology, Medicine, Multiple Myeloma +8

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors

Joaquı́n Mateo, Gopinath Ganji, Charlotte Lemech et al. · Clinical Cancer Research · 2017 · 138 citations · Full text

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors

John H. Strickler, Colin D. Weekes, John Nemunaitis et al. · Journal of Clinical Oncology · 2018 · 135 citations · Full text